JP2017508442A - Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー - Google Patents

Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー Download PDF

Info

Publication number
JP2017508442A
JP2017508442A JP2016546862A JP2016546862A JP2017508442A JP 2017508442 A JP2017508442 A JP 2017508442A JP 2016546862 A JP2016546862 A JP 2016546862A JP 2016546862 A JP2016546862 A JP 2016546862A JP 2017508442 A JP2017508442 A JP 2017508442A
Authority
JP
Japan
Prior art keywords
gene
mdm2i
cancer
tumor
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508442A5 (enExample
Inventor
ガイチウ アーチー ツェ
ガイチウ アーチー ツェ
中丸　健治
健治 中丸
田崎　康一
康一 田崎
賢司 渡辺
賢司 渡辺
剛彦 関
剛彦 関
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JP2017508442A publication Critical patent/JP2017508442A/ja
Publication of JP2017508442A5 publication Critical patent/JP2017508442A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016546862A 2014-01-14 2015-01-13 Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー Pending JP2017508442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927310P 2014-01-14 2014-01-14
US61/927,310 2014-01-14
PCT/JP2015/051157 WO2015108175A1 (en) 2014-01-14 2015-01-13 Gene signatures associated with sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017508442A true JP2017508442A (ja) 2017-03-30
JP2017508442A5 JP2017508442A5 (enExample) 2018-02-08

Family

ID=52432889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546862A Pending JP2017508442A (ja) 2014-01-14 2015-01-13 Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー

Country Status (4)

Country Link
US (1) US20160333419A1 (enExample)
EP (1) EP3094746A1 (enExample)
JP (1) JP2017508442A (enExample)
WO (1) WO2015108175A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523824A (ja) * 2015-08-03 2018-08-23 ノバルティス アーゲー 血液学的毒性バイオマーカーとしてのｇｄｆ−１５

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
JP2018538247A (ja) 2015-10-23 2018-12-27 第一三共株式会社 Ａｍｌを処置することに用いるための医薬組成物およびそれを必要とする対象においてａｍｌを処置する方法
JP6855472B2 (ja) 2015-10-23 2021-04-07 第一三共株式会社 がんを治療するためのｍｄｍ２阻害剤の投与計画
CN106512009B (zh) * 2016-10-28 2019-10-11 武汉大学 Ph同源域家族a成员3（phlda3）在治疗心肌肥厚中的应用
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2020235671A1 (ja) * 2019-05-23 2020-11-26 国立大学法人大阪大学 性ホルモン非感受性ｇｒｅｂ１陽性腫瘍の治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020502A2 (en) * 2012-07-31 2014-02-06 Novartis Ag Markers associated with human double minute 2 inhibitors
WO2015000945A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020502A2 (en) * 2012-07-31 2014-02-06 Novartis Ag Markers associated with human double minute 2 inhibitors
WO2015000945A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
[HG-U133_PLUS_2] AFFYMETRIX HUMAN GENOME U133 PLUS 2.0 ARRAY. [ONLINE]. 2003-NOV-07 UPLOADED. [RETRI, JPN6018046246, ISSN: 0004041596 *
PROC. NATL. ACAD. SCI. USA, (2006), 103, [6], P.1888-1893, JPN6018046249, ISSN: 0004041597 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523824A (ja) * 2015-08-03 2018-08-23 ノバルティス アーゲー 血液学的毒性バイオマーカーとしてのｇｄｆ−１５

Also Published As

Publication number Publication date
WO2015108175A1 (en) 2015-07-23
US20160333419A1 (en) 2016-11-17
EP3094746A1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
JP2017532959A (ja) Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
JP7128853B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2017508442A (ja) Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー
DK2817630T3 (en) Methods for predicting an anti-cancer response
JP2020031642A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
US20100137164A1 (en) Biomarkers for predicting prostate cancer progression
US20110165566A1 (en) Methods of optimizing treatment of breast cancer
KR20230011905A (ko) 파노믹 게놈 유병률 점수
KR20110111462A (ko) 암 바이오마커
JP2014509868A (ja) 癌の予後のための遺伝子発現予測因子
WO2014071279A2 (en) Gene fusions and alternatively spliced junctions associated with breast cancer
EP2861992A1 (en) Methods for head and neck cancer prognosis
US20150240312A1 (en) Copy number aberration driven endocrine response gene signature
Ong et al. A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases
US20140329714A1 (en) Stat3 activation as a marker for classification and prognosis of dlbcl patients
WO2013079188A1 (en) Methods for the diagnosis, the determination of the grade of a solid tumor and the prognosis of a subject suffering from cancer
WO2014160080A1 (en) Cancer diagnosis, treatment selection and treatment
JP6876304B2 (ja) 癌に対する薬物療法の効果の予測方法
KR102384992B1 (ko) 대장암 환자의 연령 특이적 바이오마커 및 이의 용도
CN104212884A (zh) 胰腺神经内分泌肿瘤易感基因位点及检测方法和试剂盒
JP2014501496A (ja) 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法
US20250129428A1 (en) Methods and materials for predicting the progression of prostate cancer and treating same
HK40113028A (en) Methods for predicting response to parp inhibitors
Andres A genomic approach for assessing clinical outcome of breast cancer
EP2531856A2 (en) Methods and kits used in classifying adrenocortical carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190528